摘要:
A connector assembly including a first connector configured to be movably mounted to a support structure and having a first mating terminal. The first connector is movable with respect to the support structure in an axial direction along an alignment axis. The connector assembly also includes a second connector that is configured to be movably mounted to a support panel and has a second mating terminal. The second connector is movable with respect to the support panel in a radial direction relative to an alignment axis. The second connector shifts in the radial, direction to align the first and second mating terminals when the first and second connectors engage each other in a misaligned manner. The first connector moves between a projected position and a retracted position along the alignment axis to facilitate establishing a communication pathway between the first and second mating terminals.
摘要:
A connector assembly including a first connector configured to be movably mounted to a support structure and having a first mating terminal. The first connector is movable with respect to the support structure in an axial direction along an alignment axis. The connector assembly also includes a second connector that is configured to be movably mounted to a support panel and has a second mating terminal. The second connector is movable with respect to the support panel in a radial direction relative to an alignment axis. The second connector shifts in the radial, direction to align the first and second mating terminals when the first and second connectors engage each other in a misaligned manner. The first connector moves between a projected position and a retracted position along the alignment axis to facilitate establishing a communication pathway between the first and second mating terminals.
摘要:
A class of monomeric or dimeric peptides containing a specific hexa- or heptapeptide unit in either linear or cyclic form are active tachykinin antagonists and are therefore useful in disease states in which these peptides have been implicated, such as allergic conditions, inflammation, migraine, arthritis and CNS disorders.
摘要:
A contact rail is provided including a module coupling end and a mating end. A diode mounting surface is positioned between the module coupling end and the mating end. A pivot member extends from a base of the module coupling end. The pivot member is configured to be engaged by an elongated tool. A module coupling fastener engages the base of the module coupling end. The elongated tool is configured to engage the module coupling fastener. The elongated tool is configured to pivot about the pivot member to separate the module coupling fastener from the base of the module coupling end so that a contact from a power module is receivable between the base of the module coupling end and the module coupling fastener.
摘要:
Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.
摘要:
The present invention provides R(+)-3-amino-1-hydroxypyrrolidin-2-one of formula I: ##STR1## or pharmaceutically acceptable acid addition salt thereof, which compound is useful as an anticonvulsant agent and in the treatment and/or prevention of neurodegenerative disorders.
摘要:
Compounds of formula (I), or a salt or prodrug thereof, wherein R.sup.1 represents H, C.sub.1-4 alkyl or CH.sub.2 COOH; R.sup.2 represents H or C.sub.1-4 alkyl, with the proviso that R.sup.1 and R.sup.2 are not both H; R.sup.3 and R.sup.4 each independently rely resent H, C.sub.1-, alkyl. C.sub.2-6 alkenyl C.sub.1-6 alkoxy, halo or trifluoromethyl; A.sup.1, A.sup.2, A.sup.3, and A.sup.4 each independently represent H, C.sub.1-6 alkyl, C.sub.1-6 alkenyl, C.sub.1-6 alkoxy, halo or trifluoromethyl; and A.sup.5 and A.sup.6 each independently represent H or C.sub.1-4 are tachykinin antagonists useful ##STR1##
摘要:
The present invention is directed to compounds of the formula (I) ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, and R.sup.7 are defined herein, and pharmaceutically acceptable salts thereof, which are useful as tachykinin antagonists,
摘要:
Compounds of Formula (I) and pharmaceutically acceptable salts thereof: ##STR1## wherein Q is optionally substituted phenyl or naphthyl;X and Y are each H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl or X and Y are together .dbd.O;Z is O or S;R.sup.1 is H, optionally substituted C.sub.1-6 alkyl, optionally substituted phenyl (C.sub.1-4 alkyl), C.sub.2-6 alkenyl, COC.sub.1-6 alkylhalo, COR.sup.a, COOR.sup.a, CONHR.sup.a, COC.sub.1-6 alkylNR.sup.a R.sup.b or CONR.sup.a C.sub.1-6 alkylCONR.sup.a R.sup.b ;R.sup.2 is substituted C.sub.1-6 alkyl, optionally substituted phenyl(C.sub.1-4 alkyl), C.sub.2-6 alkenyl, C.sub.1-6 alkylhalo, COR.sup.a, COOR.sup.a, CONHR.sup.a, COC.sub.1-6 alkylNR.sup.a R.sup.b or CONR.sup.a C.sub.1-6 alkylCONR.sup.a R.sup.b ;or R.sup.1 and R.sup.2 together form a chain (CH.sub.2).sub.p optionally substituted by oxo;R.sup.3 is H [or C.sub.1-6 alkyl];R.sup.4 is H, C.sub.1-6 alkyl or phenyl; andR.sup.5 is optionally substituted (CH.sub.2).sub.q phenyl; are tachykinin antagonists useful for treating pain.
摘要翻译:PCT No.PCT / GB92 / 01241 Sec。 371日期:1993年12月17日 102(e)日期1993年12月17日PCT提交1992年7月8日PCT公布。 出版物WO93 / 01165 日期1993年1月21日式(I)化合物及其药学上可接受的盐:其中Q是任选取代的苯基或萘基; X和Y各自为H,C 1-6烷基,C 2-6烯基或X和Y一起= O; Z是O或S; R 1是H,任选取代的C 1-6烷基,任选取代的苯基(C 1-4烷基),C 2-6烯基,COC 1-6烷基卤素,CORA,COORa,CONHRa,COC 1-6烷基NR a R b或CONR a C 1-6烷基CONR a R b; R 2是取代的C 1-6烷基,任选取代的苯基(C 1-4烷基),C 2-6烯基,C 1-6烷基卤代,CORA,COORa,CONHRa,COC 1-6烷基NR a R b或CONR a C 1-6烷基CONR a R b; 或R 1和R 2一起形成任选被氧代取代的链(CH 2)p; R3是H [或C1-6烷基]; R4是H,C1-6烷基或苯基; 并且R 5是任选取代的(CH 2)q苯基; 是用于治疗疼痛的速激肽拮抗剂。
摘要:
Fused tricyclic compounds of formula (I) as disclosed herein, and salts and prodrugs thereof, are tachykinin antagonists, useful for treating pain.